Prior treatment with protein-bound paclitaxel allowed if it has been six months since received or progressed on protein-bound paclitaxel and plan to continue to receive protein-bound paclitaxel with MinnelideTMcapsules
Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as anti-neoplastic therapy
History of grade 3-4 immediate hypersensitivity reaction to paclitaxel
paclitaxel
Patient must not have had prior treatment with paclitaxel or nab-paclitaxel
Patients for whom paclitaxel (or nab-paclitaxel) is being used in the curative setting, either adjuvant or neoadjuvant, and patients who would receive paclitaxel (or nab-paclitaxel) as first line therapy in a tumor type in which paclitaxel (or nab-paclitaxel) has a proven survival benefit for metastatic disease
Prior treatment with paclitaxel as part of definitive therapy regimen is acceptable, provided the patient is not intolerant of paclitaxel.
History of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil). Patients who exhibit these hypersensitivities will be eligible to receive single agent DKN-01
History of allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone or paclitaxel/nab-paclitaxel; patients with a history of mild infusion reactions with paclitaxel who were able to continue to receive paclitaxel with corticosteroid premedication will be eligible to participate, as these cases were likely related to cremaphor and not paclitaxel
Has a known sensitivity to any component of carboplatin or paclitaxel or nab-paclitaxel.
Patients with advanced or metastatic solid tumors who have disease progression after treatment with available therapies and for whom nab-paclitaxel treatment is appropriate.
Participants who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil) or to nab-paclitaxel and any of the excipients
Carboplatin or paclitaxel exposure within past 6 months.
Has a history of severe hypersensitivity reaction (e.g., generalized rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to nab-paclitaxel or anti-PD1/PDL1 or human albumin
Known hypersensitivity to pirfenidone, carboplatin, pemetrexed or paclitaxel
Prior treatment with nab-paclitaxel (abraxane)
Conditions that would prohibit intermittent administration of corticosteroids for paclitaxel premedication; however, corticosteroid can be dropped after confirming of no asthma like reaction to paclitaxel after 3 doses
Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist; no other investigational or commercial therapeutic agents may be given concurrently with the paclitaxel
The planned treatment regimen must be concurrent chemoradiation with carboplatin-paclitaxel followed by surgery
Received prior treatment with nab-paclitaxel.
FOR PARTICIPANTS WHO WILL BE RECEIVING NAB-PACLITAXEL (ALL ARMS EXCEPT ARM B1 SINGLE AGENT LEAD-IN)
No treatment with paclitaxel or nab-paclitaxel within 4 months prior to initiation of study therapy
FOR PARTICIPANTS WHO WILL NOT RECEIVE NAB-PACLITAXEL (ARM B1 SINGLE AGENT LEAD-IN ONLY)
EXCLUSION CRITERIA SPECIFIC TO PATIENTS WHO WILL BE RECEIVING NAB-PACLITAXEL (ALL ARMS EXCEPT ARM B1 SINGLE AGENT LEAD-IN)
Participants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxel
Subjects must not have received paclitaxel or nab-paclitaxel within 4 months prior to initiation of study therapy
Participants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxel
Patients receiving any other investigational agents or are unable to be treated with doxorubicin, cyclophosphamide, and paclitaxel
Patients with a histologically confirmed or presumed diagnosis of gynecologic malignancy for whom chemotherapy with paclitaxel and carboplatin is planned
Consultation with a medical oncologist at enrolling site =< 56 days prior to registration, with determination that treatment with neoadjuvant chemoradiotherapy with weekly carboplatin and paclitaxel is considered acceptable
Planned chemotherapy with combination carboplatin and paclitaxel given intravenously
History of hypersensitivity to paclitaxel or carboplatin or their excipients
Patients with known history of hypersensitivity to paclitaxel that did not resolve with pre-medication
Prior treatment with paclitaxel in the metastatic setting is not allowed (patients who received neoadjuvant paclitaxel can be included)
Patients with a history of prior therapy with paclitaxel and/or carboplatin
Known hypersensitivity to any of the components of atezolizumab or nab-paclitaxel
Must be a candidate for treatment with either carboplatin plus paclitaxel or carboplatin plus PLD
Patients must be, after evaluation by the investigator, appropriate candidates for the administration of 5 to 6 cycles of standard platinum-based combination chemotherapy (carboplatin and paclitaxel, carboplatin and liposomal doxorubicin, or carboplatin and gemcitabine) following CRS with or without HIPEC
ARM A COHORT 1: Patients must not have prior nab-paclitaxel exposure
Subjects with any tumor type (except lung) for which carboplatin plus paclitaxel chemotherapy would be appropriate • Paclitaxel Arm:
Subjects with any tumor type (except lung) for which paclitaxel chemotherapy would be appropriate • Anastrozole Arm:
Carboplatin Plus Paclitaxel Arm:
Paclitaxel Arm:
Subjects who were previously treated with paclitaxel for locally advanced and/or metastatic disease and who in the opinion of the Investigator may benefit from the combination treatment of ARQ 092 and paclitaxel may be enrolled
For subjects enrolled in the Carboplatin Plus Paclitaxel Arm or Paclitaxel Arm, concurrent standard long-term anticancer hormonal therapy with drugs including but not limited to selective estrogen receptor modulators or Gonadotropin-releasing hormone (GnRH) analogs if started at least six months before the first dose of study treatment is allowed
History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride (HCL) or the components of doxil, paclitaxel, or carboplatin
Patient is suitable to receive standard chemotherapy with radiation during weeks 2-7 (e.g. cisplatin+ etoposide or carboplatin+paclitaxel)
History of hypersensitivity to paclitaxel
ELIGIBILITY CRITERIA FOR REGISTRATION: the subject and her physician must agree to 6 cycles (a total of up to 8 cycles will be allowed) of one of the standard of care regimens allowed on this protocol; these regimens (starting dosage) include:\r\n* < 70 years of age:\r\n** R1: IV paclitaxel 175 mg/m^2 and carboplatin area under the curve (AUC) 5-6 every 21 days\r\n** R2: IV docetaxel 75 mg/m^2 and carboplatin AUC 5-6 every 21 days\r\n** R3: IV paclitaxel 80 mg/m^2 day 1, 8, and 15 and carboplatin AUC 5-6 day 1 every 21 days\r\n* >= 70 years of age may (but not required to) choose one of the following alternative regimens:\r\n** R4: IV paclitaxel 135 mg/m^2 plus IV carboplatin AUC 5 plus optional filgrastim (G-CSF) every 21 days\r\n** R5: IV paclitaxel 60 mg/m^2 day 1, 8, and 15 plus IV carboplatin AUC 5 day 1 every 21 days (day 15 paclitaxel optional)\r\n** R6: IV paclitaxel 60 mg/m^2 plus IV carboplatin AUC 2 day 1, 8, and 15 every 21 days\r\n*** Use of granulocyte colony stimulating factor is permitted, but additional chemotherapy agents (e.g. gemcitabine) or biologic agents (e.g. bevacizumab) are not; dose modifications for patients >= age 70 are allowable as indicated above; patients >= age 70 for whom the physician deems carboplatin AUC 5 to be unsafe may be treated with AUC 4
Previous inability to tolerate any dose of paclitaxel (i.e., the subject required a paclitaxel dose reduction or discontinuation).
Subjects who have history of severe hypersensitive reaction to the active ingredient or any excipients of DHP107 or IV paclitaxel.
Known allergic reaction to talimogene laherparepvec, paclitaxel, aromatase inhibitors, tamoxifen, fulvestrant, or any of their components; an exception is made if the patient will not be receiving the offending agent/component (i.e. a patient who is allergic to paclitaxel but will be receiving endocrine therapy is eligible)
Known hypersensitivity to nab-paclitaxel or any of its excipients
Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as anti-neoplastic therapy
Patients who received and progressed on the combination of carboplatin/paclitaxel will not be eligible
Participants may have received prior treatment with weekly paclitaxel; however, participants who have had progression on or within 8 weeks of their last dose of weekly paclitaxel will not be eligible
For gynecologic cancer cohort only recurrent or progressive disease within 30 days of the last dose of weekly paclitaxel or nab-paclitaxel
Subject has previously been treated with nab-paclitaxel\t\r\n* NOTE: Subjects who have had previous treatment with nab-paclitaxel will NOT be excluded if given in the adjuvant or neoadjuvant setting\r\n* Only in the metastatic setting, will subjects previously treated with nab-paclitaxel be excluded from this trial; exceptions may be made for subjects who discontinued treatment with a previous nab-paclitaxel inhibitor for reasons other than progression and as long as it has been > 12 months since discontinuation of the previous nab-paclitaxel; this exception will require prior approval from the study principal investigator (PI) at University of Kansas Medical Center (KUMC)
Subject has a known hypersensitivity to any of the excipients of nab-paclitaxel or BYL719/alpelisib
Known hypersensitivity to any component of bevacizumab or to nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation)
Patients with recurrent disease may have received prior treatment with carboplatin/paclitaxel but must have had a treatment free interval of > 6 months
Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (Cremophor).
History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 9. Currently enrolled in any other clinical protocol or investigational trial that involved administration of experimental therapy and/or therapeutic devices.
Any contraindication to the use of cisplatin, carboplatin, or paclitaxel chemotherapy
Suitable candidate for single agent nab-paclitaxel as assessed by the investigator.
Weekly paclitaxel for recurrent or persistent disease.
Non-pregnant and non-nursing. The effect of nab-paclitaxel and nivolumab on the fetus is unknown.
Prior nab-paclitaxel chemotherapy excluded.
Patients must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound; this initial treatment may have included intraperitoneal therapy, consolidation, non-cytotoxic agents (biologic/ targeted) or extended therapy administered after surgical or non-surgical assessment; if patients were treated initially with paclitaxel for their primary disease, this can have been given weekly or every 3 weeks; the most recent therapy and any therapies subsequent to initial therapy, however, cannot have contained weekly paclitaxel; if the immediate prior (most recent therapy) is the initial therapy, it may not have been with weekly paclitaxel
Has known hypersensitivity to paclitaxel
Known allergy or hypersensitivity to paclitaxel or any components used in the paclitaxel preparation or other contraindication for taxane therapy
Must have completed concurrent chemoradiation with a standard chemotherapy regimen (either cisplatin/etoposide or carboplatin/paclitaxel) and a dose of radiation ranging from 59.4-66.6Gy
Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
Known hypersensitivity to any of the components of ipilimumab, bevacizumab, or nab-paclitaxel
Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
Prior treatment with nab-paclitaxel.
History of prior paclitaxel therapy
Deemed eligible to receive neoadjuvant chemotherapy with 12 cycles of weekly taxane therapy (paclitaxel 80 mg/m2 or abraxane 100 mg/m2 if there is a shortage of paclitaxel) followed by 4 cycles of adriamycin (60 mg/m2) and cyclophosphamide (600 mg/m2) given every 2 weeks with growth-factor support
Known hypersensitivity to doxorubicin, cyclophosphamide, paclitaxel, Cremophor or medications containing Cremophor (miconazole, docetaxel, Sandimmune, nelfinavir mesylate, propofol, diazepam injection, vitamin K injection, ixabepilone, Aci-Jel) or carboplatin
Known hypersensitivity to Cremophor EL. However, participants are eligible if they have had a prior paclitaxel reaction, but subsequently tolerated the drug at rechallenge.
Known hypersensitivity to protein bound paclitaxel
Patient must not have previously received nab-paclitaxel
No known prior hypersensitivity to carboplatin, paclitaxel, bevacizumab or hydroxychloroquine or any of their components
History of known allergy or contraindications to the use of pazopanib, paclitaxel, or carboplatin
CARBOPLATIN AND PACLITAXEL ARMS: absolute neutrophil count >= 1,500/mL
CARBOPLATIN AND PACLITAXEL ARMS: platelets >= 100,000/mL
CARBOPLATIN AND PACLITAXEL ARMS: patient with neuropathies of Common Toxicity Criteria (CTC) grade 1 or less
PACLITAXEL ARM: hypersensitivity to paclitaxel or any component of the formulation
History of hypersensitivity to nab-paclitaxel or paclitaxel
Weekly paclitaxel must be an acceptable treatment option
Currently or previously treated with conventional chemotherapy, or other agents for metastatic pancreatic ductal adenocarcinoma (Arm: idelalisib + nab-paclitaxel only)
Known hypersensitivity to nab-paclitaxel (Arm: idelalisib + nab-paclitaxel), their metabolites, or formulation excipients
Patients who have experienced a previous grade 3 or 4 anaphylactic reaction to paclitaxel
Cytotoxic chemotherapy, such as dacarbazine, temozolomide, carboplatin +/-paclitaxel.
Patients with prior therapy with paclitaxel or other taxanes.
Prior treatment with PM01183 or weekly paclitaxel or nanoalbumin-paclitaxel
Patients who have previously discontinued paclitaxel-based regimes due to drug related toxicity.
have not been treated with weekly paclitaxel after first-line treatment in which weekly paclitaxel plus a platinum is permitted
Prior anaphylactic or severe hypersensitivity reaction to paclitaxel or Cremophor-containing agent.
History of or suspected allergy to nab-paclitaxel, carboplatin and human albumin or any other platinum-based therapy.
Paclitaxel therapy is appropriate for the patient and is recommended by the Investigator.
Known hypersensitivity or history of severe intolerance or toxicity to study-assigned chemotherapy. Note: History of severe hypersensitivity reactions to docetaxel (polysorbate 80-based formulations) for participants to be treated with MLN4924 + docetaxel; history of hypersensitivity to carboplatin for participants to be treated with MLN4924 + carboplatin + paclitaxel; or history of severe hypersensitivity to paclitaxel (Cremophor-based formulations) for participants to be treated with MLN4924 + carboplatin + paclitaxel in Part B.
History of intolerance or hypersensitivity to paclitaxel and/or adverse events related to paclitaxel that resulted in paclitaxel being permanently discontinued
Subjects with a known history of allergy to paclitaxel. Subjects whose allergy was due to the IV solvent (such as Cremophor®) and not paclitaxel will be eligible for this study.
Prior therapy with weekly paclitaxel for recurrent disease (administration of weekly paclitaxel as part of an upfront treatment strategy is acceptable as long as the patient had not progressed while receiving weekly paclitaxel or recurred within 4 months of receiving weekly paclitaxel)
Patients with prior paclitaxel exposure are ineligible unless they are > 6 months from the conclusion of paclitaxel-based therapy
History of severe hypersensitivity reactions to docetaxel (polysorbate 80-based formulations) for patients to be enrolled in Arm 1 (MLN4924 + docetaxel), history of hypersensitivity to carboplatin for patients to be enrolled in Arm 2 (MLN4924 + paclitaxel + carboplatin), or history of severe hypersensitivity to paclitaxel (cremophor-based formulations) for patients to be enrolled in Arm 2
Received prior paclitaxel therapy or had clinically documented reason why not administered
Known history of dose-limiting hypersensitivity reactions to paclitaxel/Cremophor EL
A history of a severe hypersensitivity reaction to nab-paclitaxel
History of allergy or hypersensitivity to nab-paclitaxel, albumin or a taxane
Prior therapy allowed but, no prior therapy with nab-paclitaxel, paclitaxel, temozolomide, dacarbazine or bevacizumab
Have completed neurotoxic chemotherapy, i.e. taxanes (paclitaxel, docetaxel) and platinum (carboplatin) at least 3 months prior to enrollment
Patients receiving the initial course of chemotherapy including \r\n* Paclitaxel 135 mg/M2 IV over 3 hours on day 1 and \r\n* Cisplatin 75 mg/M2 IP on day 2  OR  \r\n* Paclitaxel 80 mg/m2 IV days 1, 8 and 15 and \r\n* Carboplatin AUC 6 IP on day 1
Planned dose-dense chemotherapy with combination carboplatin and paclitaxel given intravenously
The patient’s previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) and considered the primary cause of the neuropathy by the medical team
Known hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast media
The patient’s previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team
Known severe hypersensitivity to paclitaxel
Subject appropriate for cytoreductive surgery and treatment with IV platinum and paclitaxel
Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide
Has a known history of hypersensitivity or allergy to pembrolizumab and any of its components and/or to any of the study chemotherapies (e.g., nab-paclitaxel, paclitaxel, gemcitabine, or carboplatin) and any of their components.
Known hypersensitivity to protein bound paclitaxel